Sionna Therapeutics, Inc. (SION)
| Market Cap | 871.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.72M |
| Shares Out | 44.11M |
| EPS (ttm) | -16.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,432 |
| Open | 20.06 |
| Previous Close | 20.11 |
| Day's Range | 19.66 - 20.88 |
| 52-Week Range | 19.26 - 25.19 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cystic fibrosis (CF). It develops nucleotide-binding domain 1 (NBD1) stabilizers that normalize CFTR function for CF patients; Galicaftor (SION-2222) and SION-2851; SION-109, an ICL4-directed CFTR corrector; and Navocaftor (SION-3067), a potentiator. Sionna Therapeutics, Inc. formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. The company was incorporated in 2019 and is based in Waltham, Massach... [Read more]
News
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic f...
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...
Sionna Therapeutics Prices Upsized Initial Public Offering
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fi...
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in ca...
Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO
Sionna Therapeutics, a Phase 2 biotech developing novel therapies for cystic fibrosis, filed on Friday with the SEC to raise up to an estimated $100 million in an initial public offering.
Sionna Therapeutics IPO Registration Document (S-1)
Sionna Therapeutics has filed to go public with an IPO on the NASDAQ.